EMEA-002665-PIP02-20
Key facts
| Active substance |
Loncastuximab tesirine
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0400/2021
|
| PIP number |
EMEA-002665-PIP02-20
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Swedish Oprhan Biovitrum AB (publ)
Email: info@sobi.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|